SynapDx Corp has secured what has been described as a 'significant investment' from Kraft Group.
US-based food company Kraft Group has made a “significant investment” into US-based SynapDx, a company which develops blood-based diagnostic test for autism spectrum disorders.
The new funds of undisclosed amount will be used to continue clinical developments.
The company has previously raised $19m in funding, $9m in series A led by Bain Capital Ventures in 2010, $6m in series B financing led by North Bridge Venture partners in 2012 and $2m in a series C round in February this year.…
